Literature DB >> 7656015

Structure of human neutrophil collagenase reveals large S1' specificity pocket.

T Stams1, J C Spurlino, D L Smith, R C Wahl, T F Ho, M W Qoronfleh, T M Banks, B Rubin.   

Abstract

The crystal structure of the catalytic domain of human neutrophil collagenase complexed with a peptide transition state analogue has been determined to a resolution of 2.1 A. The structure of the neutrophil enzyme, when compared with the three dimensional structure of the corresponding human fibroblast collagenase, shows differences in the first, S1', of the three enzyme specificity subsites on the carboxy-terminal side of the substrate scissile bond. The S1' pocket in the neutrophil collagenase is significantly larger than the equivalent site in the fibroblast enzyme, suggesting that the former enzyme has a broader range of possible substrates. Such differences also suggest approaches for the design of selective matrix metalloproteinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7656015     DOI: 10.1038/nsb0294-119

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  23 in total

Review 1.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

2.  Structural characterizations of nonpeptidic thiadiazole inhibitors of matrix metalloproteinases reveal the basis for stromelysin selectivity.

Authors:  B C Finzel; E T Baldwin; G L Bryant; G F Hess; J W Wilks; C M Trepod; J E Mott; V P Marshall; G L Petzold; R A Poorman; T J O'Sullivan; H J Schostarez; M A Mitchell
Journal:  Protein Sci       Date:  1998-10       Impact factor: 6.725

3.  Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data.

Authors:  H Brandstetter; R A Engh; E G Von Roedern; L Moroder; R Huber; W Bode; F Grams
Journal:  Protein Sci       Date:  1998-06       Impact factor: 6.725

4.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Authors:  M D Eldridge; C W Murray; T R Auton; G V Paolini; R P Mee
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

5.  Comparison of the structure of human recombinant short form stromelysin by multidimensional heteronuclear NMR and X-ray crystallography.

Authors:  P R Gooley; J F O'Connell; A I Marcy; G C Cuca; M G Axel; C G Caldwell; W K Hagmann; J W Becker
Journal:  J Biomol NMR       Date:  1996-01       Impact factor: 2.835

Review 6.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

7.  Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor.

Authors:  S R Van Doren; A V Kurochkin; W Hu; Q Z Ye; L L Johnson; D J Hupe; E R Zuiderweg
Journal:  Protein Sci       Date:  1995-12       Impact factor: 6.725

8.  X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.

Authors:  A G Pavlovsky; M G Williams; Q Z Ye; D F Ortwine; C F Purchase; A D White; V Dhanaraj; B D Roth; L L Johnson; D Hupe; C Humblet; T L Blundell
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

9.  Solution structures of stromelysin complexed to thiadiazole inhibitors.

Authors:  B J Stockman; D J Waldon; J A Gates; T A Scahill; D A Kloosterman; S A Mizsak; E J Jacobsen; K L Belonga; M A Mitchell; B Mao; J D Petke; L Goodman; E A Powers; S R Ledbetter; P S Kaytes; G Vogeli; V P Marshall; G L Petzold; R A Poorman
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

Review 10.  Structural aspects of the metzincin clan of metalloendopeptidases.

Authors:  F Xavier Gomis-Rüth
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.